Literature DB >> 10855050

Long-term postoperative stability in infantile esotropia.

F J Rowe1.   

Abstract

The purpose of this paper is to present the ocular motility status of a group of patients with infantile esotropia who underwent surgery before 2 years of age and were followed for a minimum period of 4 years until discharge from Ophthalmology and Orthoptic review. This retrospective review included 40 children with a diagnosis of infantile esotropia. There were 22 females and 18 males. The children were identified from surgical records between 1987 and 1992. Each child had surgery before the age of 2 years at an average age of 17 months (7 months to 22 months). Many patients (60%) achieved a small-angle (less than 20 prism dioptres), cosmetically acceptable strabismus. Nine patients (22.5%) achieved binocular vision postoperatively, five with microtropia, one with intermittent exotropia and three with bifoveal exophoria. The bifoveal patients did not exhibit high grade stereopsis, which may relate to the time of onset of infantile esotropia when development of cortical stereopsis is critical. Persistent amblyopia postoperatively was significantly associated with a poorer outcome and lack of binocular function.

Entities:  

Mesh:

Year:  2000        PMID: 10855050

Source DB:  PubMed          Journal:  Strabismus        ISSN: 0927-3972


  3 in total

1.  The decompensated monofixation syndrome (an American Ophthalmological Society thesis).

Authors:  R Michael Siatkowski
Journal:  Trans Am Ophthalmol Soc       Date:  2011-12

2.  Long-term follow-up of congenital esotropia in a population-based cohort.

Authors:  Curtis R Louwagie; Nancy N Diehl; Amy E Greenberg; Brian G Mohney
Journal:  J AAPOS       Date:  2008-11-06       Impact factor: 1.220

3.  Is the incidence of infantile esotropia declining?: a population-based study from Olmsted County, Minnesota, 1965 to 1994.

Authors:  Curtis R Louwagie; Nancy N Diehl; Amy E Greenberg; Brian G Mohney
Journal:  Arch Ophthalmol       Date:  2009-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.